Hikma Pharmaceuticals PLC (HIK) - Financial and Strategic SWOT Analysis Review

Document Sample
Hikma Pharmaceuticals PLC (HIK) - Financial and Strategic SWOT Analysis Review Powered By Docstoc
					              Hikma Pharmaceuticals PLC (HIK) - Financial and Strategic SWOT
                                    Analysis Review
        Reference Code: GDPH57970FSA                                                                                          Publication Date: MAR 2013

          13 Hanover Square                                  Phone              +44 20 73992760                 Revenue          1,108.7 (million USD)
          London, ENG                                        Fax                +44 20 73992761                 Net Profit       80.11 (million USD)
          W1S 1HW                                            Website            www.hikma.com                   Employees        6,165
                                                                                HIK   [London   Stock                            Pharmaceuticals           &
          United Kingdom                                     Exchange                                           Industry
                                                                                Exchange (LON)]                                  Healthcare

       Company Overview
       Hikma Pharmaceuticals PLC (Hikma Pharmaceuticals) is a UK-based pharmaceutical company. It carries out development,
       manufacturing and marketing of a broad range of generic and in-licensed pharmaceutical products in various dosage forms, such
       as solid, semi-solid, liquid and injectables. The company develops its products for central nervous system, cardiovascular, anti-
       infectives, and alimentary tract and metabolism. Geographically, the company has operations in 45 countries across the Middle
       East and North Africa region, the US and Europe.
       Key Executives                                                                SWOT Analysis
                      Name                                 Title                      Hikma Pharmaceuticals PLC, SWOT Analysis
         Said Darwazah                       Chief Executive Officer                  Strengths                              Weaknesses
         Samih Darwazah                      Chairman
                                                                                      Geographic Presence                    Performance of the Generic
         Ali Al-Husry                        Director                                                                        Business
                                                                                      Comprehensive Product
         David Rowe-Ham                      Director
                                                                                      Portfolio                              Dependence on MENA Market
         Michael Ashton                      Director
        Source: Annual Report, Company Website, Primary and Secondary
        Research, GlobalData                                                          Opportunities                          Threats

       Share Data                                                                     Strategic Acquisition                  Competitive Pressures from
         Hikma Pharmaceuticals PLC                                                                                           Generic Manufacturers
                                                                                      Strategic Developments
        Share Price (USD) as on 22-Mar-                                10.28                                                 Government Regulations
        2013
        EPS (USD)                                                        0.41
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research,
        Market Cap (million USD)                                       3,085         GlobalData

        Enterprise Value (million USD)                                 3,577
        Shares Outstanding (million)                                     197
       Source: Annual Report, Company Website, Primary and Secondary
       Research, GlobalData

       Financial Performance                                                         Recent Developments
                                                                                      Mar 13, 2013         Hikma Pharma Reports Preliminary Revenue
                                                                                                           Of $1.1 Billion In 2012
                                                                                      Nov 02, 2012         Hikma Pharma Halts Production At West-Ward
                                                                                                           Plant Over Compliance Issues, Provides
                                                                                                           Interim Management Update
                                                                                      Aug 16, 2012         Hikma Pharma Reports Revenue Of $532.3m
                                                                                                           In H1 2012
                                                                                      Apr 24, 2012         Hikma Pharma Supports National Strategy To
                                                                                                           Combat Chronic Diseases
       Source: Annual Report, Company Website, Primary and Secondary                 Source: Annual Report, Company Website, Primary and Secondary Research,
       Research, GlobalData                                                          GlobalData




Hikma Pharmaceuticals PLC (HIK) - Financial and Strategic SWOT                                                                 Reference Code: GDPH57970FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                     Page 1
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Table of Contents
       Table of Contents ............................................................................................................................................................................... 2
          List of Tables .................................................................................................................................................................................. 4
          List of Figures ................................................................................................................................................................................. 4
       Section 1 - About the Company.......................................................................................................................................................... 5
       Hikma Pharmaceuticals PLC - Key Facts ........................................................................................................................................... 5
       Hikma Pharmaceuticals PLC - Key Employees .................................................................................................................................. 6
       Hikma Pharmaceuticals PLC - Key Employee Biographies ................................................................................................................ 7
       Hikma Pharmaceuticals PLC - Major Products and Services ............................................................................................................. 8
       Hikma Pharmaceuticals PLC - History................................................................................................................................................ 9
       Hikma Pharmaceuticals PLC - Company Statement ........................................................................................................................ 11
       Hikma Pharmaceuticals PLC - Locations And Subsidiaries.............................................................................................................. 12
          Head Office ................................................................................................................................................................................... 12
          Other Locations & Subsidiaries ..................................................................................................................................................... 12
       Section 2 – Company Analysis ......................................................................................................................................................... 14
       Hikma Pharmaceuticals PLC - Business Description ....................................................................................................................... 14
       Hikma Pharmaceuticals PLC - Corporate Strategy .......................................................................................................................... 16
       Hikma Pharmaceuticals PLC - SWOT Analysis................................................................................................................................ 17
          SWOT Analysis - Overview........................................................................................................................................................... 17
          Hikma Pharmaceuticals PLC - Strengths ...................................................................................................................................... 17
             Strength - Geographic Presence ............................................................................................................................................... 17
             Strength - Comprehensive Product Portfolio ............................................................................................................................. 17
             Strength - Strong Partners Base ............................................................................................................................................... 17
             Strength - Consistent Increase in Revenue ............................................................................................................................... 17
          Hikma Pharmaceuticals PLC - Weaknesses................................................................................................................................. 18
             Weakness - Performance of the Generic Business ................................................................................................................... 18
             Weakness - Dependence on MENA Market .............................................................................................................................. 18
          Hikma Pharmaceuticals PLC - Opportunities ................................................................................................................................ 18
             Opportunity - Strategic Acquisition ............................................................................................................................................ 18
             Opportunity - Strategic Developments....................................................................................................................................... 18
             Opportunity - Market Potential: Cancer ..................................................................................................................................... 19
          Hikma Pharmaceuticals PLC - Threats ......................................................................................................................................... 19
             Threat - Competitive Pressures from Generic Manufacturers ................................................................................................... 19
             Threat - Government Regulations ............................................................................................................................................. 19
             Threat - Uncertain R&D Outcomes ........................................................................................................................................... 19
       Hikma Pharmaceuticals PLC - Key Competitors .............................................................................................................................. 20
       Section 3 – Company Financial Ratios ............................................................................................................................................. 21
       Financial Ratios - Capital Market Ratios........................................................................................................................................... 21
       Financial Ratios - Annual Ratios ...................................................................................................................................................... 21
       Performance Chart ........................................................................................................................................................................... 23
       Financial Performance...................................................................................................................................................................... 23
       Financial Ratios - Interim Ratios....................................................................................................................................................... 24
       Financial Ratios - Ratio Charts ......................................................................................................................................................... 25
       Section 4 – Company’s Lifesciences Financial Deals and Alliances ................................................................................................ 26
          Hikma Pharmaceuticals PLC, Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 .............................................. 26
          Hikma Pharmaceuticals PLC, Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 .............................................. 27


Hikma Pharmaceuticals PLC (HIK) - Financial and Strategic SWOT                                                                                                 Reference Code: GDPH57970FSA
Analysis Review
Source : www.globalcompanyintelligence.com                                                                                                                                                                Page 2
© GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form
       Hikma Pharmaceuticals PLC, Recent Deals Summary .................................................................................................................... 28
       Section 5 – Company’s Recent Developments ................................................................................................................................ 29
          Hikma Pharmaceuticals PLC, Recent Developments ................................................................................................................... 29
             Mar 13, 2013: Hikma Pharma Reports Preliminary Revenue Of $1.1 Billion In 2012 ................................................................ 29
             Nov 02, 2012: Hikma Pharma Halts Production At West-Ward Plant Over Compliance Issues, Provides Interim Management
             Update....................................................................................................................................................................................... 30
             Aug 16, 2012: Hikma Pharma Reports Revenue Of $532.3m In H1 2012 ................................................................................ 31
             Apr 24, 2012: Hikma Pharma Supports National Strategy To Combat Chronic Diseases ......................................................... 31
             Mar 14, 2012: Hikma Pharma Reports Revenue Of $918m In 2011 .........................
				
DOCUMENT INFO
Description: Hikma Pharmaceuticals PLC (Hikma Pharmaceuticals) is a UK-based pharmaceutical company. It carries out development, manufacturing and marketing of a broad range of generic and in-licensed pharmaceutical products in various dosage forms, such as solid, semi-solid, liquid and injectables. The company develops its products for central nervous system, cardiovascular, anti-infectives, and alimentary tract and metabolism. Geographically, the company has operations in 45 countries across the Middle East and North Africa region, the US and Europe.
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.